AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab and chemotherapy for frontline treatment of metastatic
BOSTON --(BUSINESS WIRE)--Jul. 23, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026
TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases Approximately 5% of
BOSTON --(BUSINESS WIRE)--Jul. 2, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock
Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or standard-of-care chemotherapy supports broad development strategy including
90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature BOSTON --(BUSINESS WIRE)--Jun. 17, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to
TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer VS-7375
Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET BOSTON --(BUSINESS WIRE)--Jun. 15, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company
Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L
BOSTON --(BUSINESS WIRE)--May 27, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies
BOSTON --(BUSINESS WIRE)--May 26, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors.
BOSTON --(BUSINESS WIRE)--May 12, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor
Available at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship BOSTON --(BUSINESS WIRE)--May 8, 2026-- Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials “VS-7375 TARGET-D Clinical Program” in 2L PDAC, 2L/3L NSCLC and 2L+ CRC VS-7375 TARGET-D 101
Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer with a high rate of recurrence affecting more than 80% of patients Integrated healthcare professional (HCP) and patient campaign features new websites and expanded digital resources about the first and only treatment specifically
BOSTON --(BUSINESS WIRE)--Apr. 23, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026
Patients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of response with a median follow-up of two years 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type recurrent LGSOC remained
BOSTON --(BUSINESS WIRE)--Apr. 2, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees.
Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical pancreatic, lung, and colorectal cancer models, VS-7375 (dual ON/OFF inhibitor) showed deeper and more sustained tumor regression
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial BOSTON --(BUSINESS WIRE)--Mar. 17, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients
AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a